OncoMatch/Clinical Trials/NCT06703398
A Study of GC101 TIL in Advanced Melanoma
Is NCT06703398 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including GC101 TIL and dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin for melanoma.
Treatment: GC101 TIL · dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin — 98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF V600 mutation
if knowed with BRAF V600 mutate, then need to failed to BRAF/MEK inhibitor
Allowed: NRAS mutation
if knowed with NRAS mutate, then need to failed to Tunlametinib
Disease stage
Required: Stage IV
Patients with unresectable advanced, recurrent or metastatic melanoma (excluding uveal melanoma); There are still at least 1 measurable lesion (according to RECIST1.1 criteria ) even after TIL sampling and resection of surgically resectable tissue
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: anti-PD-1 therapy
Patients who have failed or resisted to PD-1 antibodies
Must have received: systemic therapy
Patients must have failed or resisted to at least two frontlines systemic tehrapy
Must have received: BRAF inhibitor
if knowed with BRAF V600 mutate, then need to failed to BRAF/MEK inhibitor
Must have received: MEK inhibitor
if knowed with BRAF V600 mutate, then need to failed to BRAF/MEK inhibitor
Must have received: MEK inhibitor (Tunlametinib)
if knowed with NRAS mutate, then need to failed to Tunlametinib
Cannot have received: TIL cell therapy
Exception: within 6 months
There is a history of TIL cell therapy, allogeneic T cell therapy, or NK cell therapy within 6 months
Cannot have received: allogeneic T cell therapy
Exception: within 6 months
There is a history of TIL cell therapy, allogeneic T cell therapy, or NK cell therapy within 6 months
Cannot have received: NK cell therapy
Exception: within 6 months
There is a history of TIL cell therapy, allogeneic T cell therapy, or NK cell therapy within 6 months
Cannot have received: drug under study
Exception: within 28 days prior to screening
Patients receive any drug under study within 28 days prior to screening
Lab requirements
Blood counts
With sufficient hematology
Kidney function
With sufficient end-organ function
Liver function
With sufficient end-organ function
With sufficient hematology and end-organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06703398 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TIL cell therapy, allogeneic T cell therapy, NK cell therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages